Karolina Stavlis
Head of Investor Relations
Replay available
RaySearch Laboratories AB (publ) (STO: RAY_B) Q1 2026 earnings conference call, held 2026-04-29. Replay captured from the company's public earnings webcast.

Head of Investor Relations
CEO and Founder
CFO
Analyst, MBA Committee
Analyst, Red Eye
Analyst
Watch the replay and follow the connected company analysis, news, and investor updates for Raysearch Laboratories Ab Class B.
WEBVTT 00:00:01.718 -- 00:00:06.744 Welcome to Research Presentation of the First Quarter 2022. 00:00:06.744 -- 00:00:10.989 My name is Karolina Stavlis, and I'm Head of Investor Relations. 00:00:10.989 -- 00:00:15.995 As usual, our CEO and founder, Johan Löf, and our CFO, Nina Grönberg, 00:00:15.995 -- 00:00:20.401 will walk you through the key highlights and financial results of the quarter. 00:00:20.401 -- 00:00:23.825 After the presentation, we will open the floor for questions. 00:00:23.825 -- 00:00:27.569 Simply raise your hand in teams to ask a question live. 00:00:27.569 -- 00:00:32.887 And with that short introduction, I will now hand over to you, Johan. 00:00:32.887 -- 00:00:37.271 Thank you, Carolina, and welcome again, everyone. 00:00:37.271 -- 00:00:38.753 I 00:00:38.753 -- 00:00:44.538 apologize for my voice. I have a cold, as you can tell. 00:00:44.538 -- 00:00:48.022 Before we dive into the results and highlights, 00:00:48.022 -- 00:00:52.744 let me start with a quick overview of Razor's business. 00:00:56.089 -- 00:01:02.453 So Razor is a software company, and we focus on, 00:01:08.594 -- 00:01:11.435 and recommend. 00:01:12.239 -- 00:01:18.026 What we see here is a schematic view of a comprehensive cancer center. 00:01:18.026 -- 00:01:23.994 Although research has been focused on radiation therapy for the first 25 years, 00:01:23.994 -- 00:01:29.982 we are now about to expand into the other areas of cancer therapy, into chemotherapy, 00:01:29.982 -- 00:01:35.469 surgery, and liver ablation, for example. So everything that goes on in a comprehensive 00:01:35.469 -- 00:01:37.469 cancer 00:01:40.471 -- 00:01:42.711 I think 00:01:47.183 -- 00:01:52.432 it's important to look at the long-term performance 00:01:52.432 -- 00:01:54.315 on research. 00:01:54....